olmesartan has been researched along with candesartan in 39 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 1,929 | 412 | 589 |
| Protein | Taxonomy | olmesartan (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (17.95) | 29.6817 |
| 2010's | 28 (71.79) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Foster, H; Foster, R; Philippou, H; Wilson, C | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Asano, Y; Fujita, M; Hirata, YL; Kim, J; Kitakaze, M; Minamino, T; Miyatsuka, T; Okuda, H; Takashima, S; Tomoike, H; Tsukamoto, O | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Imai, K; Tsunoda, M; Yamagishi, M; Yanagisawa, T | 1 |
| Kuji, T; Masuda, S; Okano, Y; Tamura, K; Tochikubo, O; Umemura, S | 1 |
| Falvey, H; Lowy, A; Müller, E; Nixon, RM | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Masuda, S; Okano, Y; Ozawa, M; Tamura, K; Tochikubo, O; Umemura, S | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y | 1 |
| Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y | 1 |
| Friedrich, D; Gortner, L; Herkenrath, P; Hoppe, B; Hünseler, C; Kattner, E; Körber, F; Lindner, U; Müller, A; Oberthuer, A; Paneitz, A; Roth, B; Schaible, T; Schmitt, K; Welzing, L | 1 |
| Belsey, JD | 1 |
| Asai, S; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y | 1 |
| Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I | 1 |
| Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Afantitis, A; Baldus, J; Christodouleas, D; Fotakis, C; Glaubitz, C; Hodzic, A; Kritsi, E; Mali, G; Mavromoustakos, T; Megariotis, G; Melagraki, G; Ntountaniotis, D; Pabst, G; Papadopoulos, MG; Potamitis, C; Rappolt, M; Zervou, M; Zoumpoulakis, P | 1 |
| Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T | 1 |
| Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C | 2 |
| Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC | 1 |
| Daikuhara, H; Fukunaga, K; Ohshima, T | 1 |
| Komano, H; Liu, J; Liu, S; Maeda, T; Tanabe, C; Zou, K | 1 |
| Asner, R; Bayer, A; Kopf, W; Letzel, M; Schüssler, W; Sengl, M; Weiß, K | 1 |
| Izumikawa, Y; Kato, H; Kojima, K; Kubo, E; Nagura, M; Nosaka, H; Shima, T; Shimada, M; Shiraishi, T; Tanemoto, M; Tomioka, S; Uchida, S; Ueda, S; Yano, H | 1 |
| Etoh, T; Kita, T; Kitamura, K; Nakada, S; Ohya, Y; Sakima, A; Shimokubo, T; Takishita, S; Tamaki, N; Yokota, N | 1 |
| Bayer, A; Greco, G; Grosse, S; Heermann, A; Letzel, M; Letzel, T; Lucke, T; Schulz, W; Schüssler, W; Sengl, M | 1 |
| Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M | 1 |
| Clifford, PS; Davis, MJ; Hill, MA; Hong, K; Hong, Z; Meininger, GA; Sun, Z; Yang, Y; Zhao, G | 1 |
| Busby, J; Cardwell, CR; Hughes, C; Johnston, BT; McMenamin, Ú; Spence, A | 1 |
| Jóźwiak, K; Kocki, T; Targowska-Duda, KM; Turski, WA; Wnorowski, A; Zakrocka, I | 1 |
| Lauder, L; Mahfoud, F; Meyer, MR; Vollmer, AC; Wagmann, L | 1 |
2 review(s) available for olmesartan and candesartan
| Article | Year |
|---|---|
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
13 trial(s) available for olmesartan and candesartan
| Article | Year |
|---|---|
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Autonomic Nervous System; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Health Surveys; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Quality of Life; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Middle Aged; Natriuretic Peptide, Brain; Peptidyl-Dipeptidase A; Tetrazoles | 2010 |
Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Quality of Life; Sympathetic Nervous System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glycemic Index; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Tetrazoles | 2010 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acid-Binding Proteins; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome | 2010 |
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Topics: Aged; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Benzimidazoles; Biphenyl Compounds; Cardiac Surgical Procedures; Compliance; Drug Substitution; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome | 2011 |
Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Imidazoles; Japan; Losartan; Male; Middle Aged; Prospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Substitution; Female; Heart Rate; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Prospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan | 2013 |
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Prospective Studies; Systole; Tetrazoles; Treatment Outcome | 2013 |
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; White People | 2014 |
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Telmisartan; Tetrazoles | 2014 |
24 other study(ies) available for olmesartan and candesartan
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Endothelial Cells; Gene Silencing; Humans; Imidazoles; NF-kappa B; Promoter Regions, Genetic; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA Interference; RNA, Messenger; Tetrazoles; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2006 |
Study of the acute cardiovascular effects of several antihypertensive agents with the measurement of plasma catecholamines in mice.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Captopril; Catecholamines; Chromatography, High Pressure Liquid; Heart Rate; Imidazoles; Luminescence; Male; Mice; Mice, Inbred C57BL; Nicardipine; Nitroprusside; Oxalates; Reproducibility of Results; Sensitivity and Specificity; Tetrazoles; Time Factors | 2009 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natriuretic Factor; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Echocardiography; Gene Expression; Hemodynamics; Imidazoles; Losartan; Male; Mice; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Apgar Score; Benzimidazoles; Biphenyl Compounds; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; Hypertension, Pulmonary; Imidazoles; Infant, Newborn; Kidney; Lung; Male; Oligohydramnios; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Renal Insufficiency; Skull; Tetrazoles; Ultrasonography, Prenatal; Valine; Valsartan | 2011 |
Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Decision Making; Humans; Hypertension; Imidazoles; Outcome Assessment, Health Care; Tetrazoles; United Kingdom | 2011 |
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrogen; Cholesterol; Cholesterol, LDL; Cohort Studies; Creatinine; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Imidazoles; Kidney; Lipid Metabolism; Male; Middle Aged; Potassium; Retrospective Studies; Tetrazoles; Triglycerides | 2011 |
Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cell Membrane; Imidazoles; Lipid Bilayers; Molecular Conformation; Receptor, Angiotensin, Type 1; Tetrazoles; Thermodynamics; Valine; Valsartan | 2012 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Differential effects of angiotensin II receptor blockers on Aβ generation.
Topics: Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Fibroblasts; Imidazoles; Losartan; Mice, Inbred C57BL; Mice, Knockout; Peptide Fragments; Phosphatidylinositol 3-Kinases; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Tetrazoles; Valine; Valsartan | 2014 |
Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biodegradation, Environmental; Biphenyl Compounds; Chromatography, Liquid; Environmental Monitoring; Germany; Imidazoles; Irbesartan; Mass Spectrometry; Molecular Structure; Rivers; Tetrazoles; Thiophenes; Valine; Valsartan; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2014 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Drug Costs; Drug Substitution; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Nephrology; Patient Satisfaction; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Retrospective Studies; Surveys and Questionnaires; Telmisartan; Tetrazoles; Valsartan | 2015 |
Differences in 24-h blood pressure profile of Japanese hypertensive patients under ARB treatment.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Sectional Studies; Female; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Therapeutic Equivalency | 2015 |
LC-MS screening techniques for wastewater analysis and analytical data handling strategies: Sartans and their transformation products as an example.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chromatography, Liquid; Environmental Monitoring; Imidazoles; Irbesartan; Laboratories; Mass Spectrometry; Tetrazoles; Wastewater; Water Pollutants, Chemical; Water Purification; Workflow | 2015 |
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Oxadiazoles; Self Care; Telmisartan; Tetrazoles; Time Factors; Valsartan | 2016 |
Mechanical activation of angiotensin II type 1 receptors causes actin remodelling and myogenic responsiveness in skeletal muscle arterioles.
Topics: Abdominal Muscles; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Biphenyl Compounds; Captopril; Cells, Cultured; Diglycerides; Imidazoles; Indoles; Losartan; Male; Maleimides; Muscle Development; Muscle Fibers, Skeletal; Pressure; Protein Kinase C; Pyridines; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents | 2016 |
Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Child; Child, Preschool; Cohort Studies; Diabetic Neuropathies; Esophageal Neoplasms; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Infant; Infant, Newborn; Losartan; Male; Middle Aged; Registries; Stomach Neoplasms; Survival Analysis; Tetrazoles; Young Adult | 2018 |
Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kynurenic Acid; Losartan; Male; Rats, Wistar; Telmisartan; Tetrazoles; Transaminases; Valsartan | 2019 |
Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Fluids; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Hypertension; Imidazoles; Liquid-Liquid Extraction; Metoprolol; Patient Compliance; Pilot Projects; Plasma; Reference Values; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles | 2021 |